October 3, 2011
The results of the pivotal PIII study BOLERO-2 showed that the hormonal therapy exemestane plus the mTOR (mammalian target of rapamycin) inhibitor Afinitor (everolimus) significantly increased progression-free survival (PFS) compared to exemestane alone in post-menopausal women with ER-positive, HER2-negative advanced...read more